1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Cardiff Aims To Change Standard Of Care For Some Colorectal Cancers

 
• By Jessica Merrill

Phase II data for onvansertib in first-line RAS-mutated metastatic colorectal cancer demonstrated impressive early efficacy and underpinned a $40m fundraising for the company.

(Shutterstock)
Key Takeaways
  • Cardiff believes the PLK1 inhibitor onvansertib could be a new standard of care for RAS-mutant first-line metastatic colorectal cancer in combination with chemotherapy and bevacizumab.
  • The company reported Phase II data from 30 evaluable patients in an ongoing study, showing an impressive overall response rate.
  • Onvansertib works better in patients who have not yet been exposed to bevacizumab, making it a better option as a first-line treatment where patients are bevacizumab-naïve.

 

Cardiff Oncology believes it is on track to upend the standard of care for patients with RAS-mutated metastatic colorectal cancer (mCRC), based on positive early Phase II data testing the...

The company announced data from the first 30 evaluable patients in the randomized CRDF-004 trial on 10 December, coinciding with a $40m fundraising through an underwritten stock offering that will...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

More from R&D

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.